pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
BOEHRINGER INGELHEIM · news · pharmadog
← back to BOEHRINGER INGELHEIM
News mentioning BOEHRINGER INGELHEIM
50
stories
Jul 30, 26
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
Jul 29, 26
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
Jul 21, 26
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
Jul 17, 26
How well are AI-discovered drugs faring in the clinic?
biopharma dive
Jul 8, 26
Novartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugs
endpoints
Jul 2, 26
A PureTech startup banks $180M for a new IPF drug
biopharma dive
Jun 11, 26
STAT+: An obesity drug deep-dive, and peptides move mainstream
stat
Jun 8, 26
Major readouts from the annual diabetes conference
stat
Jun 7, 26
#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
endpoints
Jun 7, 26
STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drug
stat
Jun 4, 26
Lilly, Boehringer retrench in Germany on proposed health spending cuts
endpoints
Jun 4, 26
STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
stat
May 19, 26
STAT+: Pharmalittle: We’re reading about a Supreme Court setback for pharma, TrumpRx expands and much more
stat
May 18, 26
STAT+: Supreme Court rejects challenge to Medicare drug price negotiation
stat
May 12, 26
Alkermes' narcolepsy Phase 3 success; Boehringer's antibody deal
endpoints
May 1, 26
Boehringer appoints pharma veteran for corporate affairs post; BlueRock CSO heads for the exit
endpoints
Apr 30, 26
Avalyn, in pursuit of better lung drugs, banks $300M in an IPO
biopharma dive
Apr 28, 26
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
biopharma dive
Apr 28, 26
STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
stat
Apr 28, 26
Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
endpoints
← prev
page 2 of 2
next →
